Date:October 04, 2025
Kigali, Rwanda and San Francisco, USA -- Bio Usawa is pleased to congratulate Dr. Sabin Nsanzimana, Rwanda’s Minister of Health, on being named among TIME Magazine’s World’s Most Influential Rising Stars.
The recognition reflects Dr. Sabin’s leadership and Rwanda’s commitment to strengthening health systems. Under his guidance, Rwanda has continued to advance practical and innovative approaches that focus on equity, resilience, and the smart use of technology to improve healthcare delivery.
"At Bio Usawa, we applaud Dr. Sabin for this recognition and remain inspired to advance equitable health solutions across the continent," said Dr. Menghis Bairu, Bio Usawa CEO, President & Co-Founder. "His leadership exemplifies the vision and commitment needed to strengthen health systems and expand access to care."
Bio Usawa looks forward to continuing to work with the Ministry of Health in our shared mission of making safe, affordable, and high-quality biotherapies more accessible to patients across Rwanda, Africa and beyond.
Bio Usawa is Rwanda's leading biotechnology company dedicated to democratizing access to life-saving biopharmaceuticals across Africa. Founded on the principle that geographic location should not determine healthcare outcomes, the company specializes in developing and manufacturing affordable, high-quality monoclonal antibodies targeting cancer, diabetes complications, infectious diseases, and autoimmune conditions. Bio Usawa's leadership team brings decades of experience from leading global biotech companies and international regulatory agencies.
Patrick Lukulay, PhD, Bio Usawa’s Chief Operating Officer, will represent Bio Usawa at the 2nd African Healthcare Manufacturing Trade Exhibition and Con…
October 2025Bio Usawa congratulates RIIO’s October, 2025 graduating class, as well as Dr. Wanjiku (Ciku) Mathenge, the Institute’s Founder and Director of Training …
October 2025Bio Usawa extends congratulations to the Ethiopian Food and Drug Authority (EFDA) on achieving WHO Maturity Level 3 (ML3) recognition this week.
October 2025